Deep learning-based classifier for carcinoma of unknown primary using methylation quantitative trait loci
Cancer of unknown primary (CUP) constitutes between 2% and 5% of human malignancies and is among the most common causes of cancer death in the United States. Brain metastases are often the first clinical presentation of CUP; despite extensive pathological and imaging studies, 20%-45% of CUP are never assigned a primary site. DNA methylation array profiling is a reliable method for tumor classification but tumor-type-specific classifier development requires many reference samples. This is difficult to accomplish for CUP as many cases are never assigned a specific diagnosis. Recent studies identified subsets of methylation quantitative trait loci (mQTLs) unique to specific organs, which could help increase classifier accuracy while requiring fewer samples. We performed a retrospective genome-wide methylation analysis of 759 carcinoma samples from formalin-fixed paraffin-embedded tissue samples using Illumina EPIC array. Utilizing mQTL specific for breast, lung, ovarian/gynecologic, colon, kidney, or testis (BLOCKT) (185k total probes), we developed a deep learning-based methylation classifier that achieved 93.12% average accuracy and 93.04% average F1-score across a 10-fold validation for BLOCKT organs. Our findings indicate that our organ-based DNA methylation classifier can assist pathologists in identifying the site of origin, providing oncologists insight on a diagnosis to administer appropriate therapy, improving patient outcomes.
Authors
- Christopher William (ORCID: https://orcid.org/0000-0001-8933-1639)
- Sarra Belakhoua (ORCID: https://orcid.org/0009-0008-0917-4759)
- Sarah Chiang (ORCID: https://orcid.org/0000-0001-9698-0936)
- David Zagzag (ORCID: https://orcid.org/0000-0002-2331-0613)
- Kristyn Galbraith (ORCID: https://orcid.org/0000-0002-5660-866X)
- Varshini Vasudevaraja (ORCID: https://orcid.org/0000-0001-9678-6375)
- Arline Faustin (ORCID: https://orcid.org/0000-0002-1147-9665)
- André L. Moreira (ORCID: https://orcid.org/0000-0003-1857-3774)
- Camila Fang (ORCID: https://orcid.org/0000-0002-8477-1253)
- Jonathan Serrano (ORCID: https://orcid.org/0000-0002-2839-9573)
- Kyung Park (ORCID: https://orcid.org/0000-0001-6714-6619)
- Farbod Darvishian (ORCID: https://orcid.org/0000-0002-9883-1982)
- Adam D. Walker (ORCID: https://orcid.org/0000-0003-3754-838X)
- Matija Snuderl (ORCID: https://orcid.org/0000-0003-0752-0917)
- Misha Movahed-Ezazi (ORCID: https://orcid.org/0000-0002-9249-5498)
- Chanel Schroff
- Yiying Yang (ORCID: https://orcid.org/0000-0001-7755-7956)
- Andres Acosta (ORCID: https://orcid.org/0000-0002-1324-6312)
Institutions
- Indiana University Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- NYU Langone Health (US)
- Indiana University – Purdue University Indianapolis (US)
- New York University (US)
Publication Details
- Journal
- Journal of Neuropathology & Experimental Neurology
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1093/jnen/nlae123
- Citations
- 1
- Primary Topic
- Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Eli Lilly and Company